- Home
- About us
- Commitment to diversity
- Awards and recognition
Awards and recognition
Find out more| GSK receives a perfect score for equality |  Close |
|---|
GSK receives perfect score for corporate equality from Human Rights Campaign Foundation
Released: 27 January 2006
GSK has received a 'perfect score' for corporate equality in an annual report card issued by the US-based Human Rights Campaign Foundation.
In its 2005 Corporate Equality Index, the foundation measures corporate America's treatment of gay, lesbian, bisexual and transgender employees, consumers and investors. GSK is listed with 100 other companies that have attained perfect scores.
Corporations are rated on a scale from zero to 100 on key criteria, including protection against discrimination based on sexual orientation and gender identity, parity of health care benefits for domestic partners and other criteria. Only companies with a perfect score of 100 percent were included in the "Best Places to Work for GLBT Equality" list.
In addition, the foundation has issued a new online resource in which GSK is listed with other companies as the "Best Places to Work for GLBT Equality." The site (www.hrc.org/placestowork) gives job seekers the information they need to find out which employers support gay, lesbian, bisexual and transgender employees and consumers.
The Human Rights Campaign Foundation is the educational arm of the Human Rights Campaign, the largest US lesbian, gay, bisexual and transgender political organisation with members. It educates the public to ensure that LGBT Americans can be open, honest and safe at home, at work and in the community.
| GSK ranks top across all sectors in new ethical rating | Close |
|---|
GSK ranks top across all sectors in new ethical rating
Released: 18 January 2006
GlaxoSmithKline has been ranked first in a new ethical ranking of the world's largest companies. The company was rated first in the Best Ethical Score category in both the pharmaceutical sector, and across all sectors. The analysis was carried out by an independent Swiss company, Covalence.
250 multinational companies were analysed in ten major sectors. The reputation index is based on an analysis of 6,000 sources of publicly available qualitative information. This includes media and websites. The data is classified according to 45 criteria of business contribution to human development such as labour standards, waste management, product social utility or human rights policy. The scoring system is straightforward, with positive news being awarded +1 and negative news –1. The overall score is therefore the numerical difference in the number of positive and negative pieces of data.
Pharmaceutical companies were well represented in the top ten. Apart from GSK, Merck, BMS and Boehringer Ingelheim are ranked 2, 3 and 9 respectively.
| GSK receives a perfect score | Close |
|---|
US Human Rights Campaign Foundation gives GSK a perfect score
Released: 26 September 2005
GlaxoSmithKline has received a perfect score of 100 per cent from the US Human Rights Campaign Foundation's 2005 Corporate Equality Index, an annual report card on corporate America's treatment of gay, lesbian, bisexual and transgender (GLBT) employees, customers and investors.
The perfect rating was pursued by a network of RTP employees who participate in the company's diversity initiative and in the Gay and Lesbian Support Network (GLSN). The networks –– associations of employees who have common interests –– provide resources to the business as well as professional growth and personal support for the participants. They advise on employee recruitment, retention, and external marketing efforts. Current US networks include the African American Alliance, the Asian Employee Support Group, the Gay and Lesbian Support Network, and the Hispanic Network. Women's Leadership groups are also a key component of GSK's diversity strategy.
"This recognition indicates that GSK is committed to creating an inclusive environment for all employees, customers, and external stakeholders, and in particular, for those who are members of the GLBT community," said US Pharma HIV Marketing VP Peter Hare, who is GLSN executive sponsor.
Consumer Healthcare President Jack Ziegler, who is executive sponsor of GSK's diversity initiative, noted that the networks have contributed to GSK's ability to respond to multicultural customers' needs, and to collaborate more effectively with community leaders to provide better healthcare solutions for underserved groups. "Our diversity initiative, including our employee networks, is a win–win for GSK, our customers, patients, and communities."
| GSK named one of 100 best US companies | Close |
|---|
Working Mother magazine names GSK to list of 100 best US companies
Released: 12 September 2005
Working Mother magazine has named GSK one of the 100 best companies in the US. This is GSK's fifth year to receive the award. The recognition speaks not only to the fact that GSK provides a supportive environment for working mothers, but it also shows GSK's continued commitment to making GSK a great place to work for all employees. The listing appears in the October issue of the publication.
This year, particular weight was given to questions in three areas: flexible scheduling, childcare options, and time off for new parents.
To apply for the Working Mother 100 Best, GSK completed a 550–question application with detailed information on eight areas of work/life. The company scored "above average" in five of the eight categories: total compensation, childcare, family–friendly programmes, advancement of women, and work/life culture. The company scored "high–average" to "average" in the remaining three areas –– culture, flexibility and parental leave –– and placed overall in the second quintile.
The 100 Best listing has been Working Mother's signature initiative for the past 20 years. It is a benchmark for work/life practices in corporate America.
GSK will be honoured at an awards ceremony at the Work/Life Congress in New York in October.
| GlaxoSmithKline diversity awards focus on customers, patients and communities | Close |
|---|
GlaxoSmithKline diversity awards focus on customers, patients and communities
Released: 27 June 2005
Award–winning projects were recognized at GlaxoSmithKline today for their focus on serving diverse customers, patients, and communities. At the company's third annual Multicultural Marketing and Diversity Awards, eight GSK team leaders representing more than 150 contributors from across the world described their innovative ideas at an awards ceremony in Research Triangle Park, North Carolina.
Jack Ziegler, worldwide President of GSK's Consumer Healthcare division and executive sponsor of the company's diversity initiative, noted that the company was making good progress in responding to the needs of multicultural customers, and in particular collaborating more effectively with community leaders to provide better healthcare solutions for underserved groups.
From Birmingham, UK, a team worked to raise smoking cessation awareness with ethnic populations who have much higher–than–average smoking habits. Another successful marketing team focused on Asian American patients at high risk for chronic hepatitis B. A winning entry from the US Consumer Healthcare division described progress in bringing products previously sold only in Latin America to serve the growing Mexican–American population in the US. Also from US Consumer Healthcare, GSK Spanish speaking employees were recognized for helping the company understand and serve the US Latino community by influencing advertising for an unmet dental care problem.
Two future–oriented projects aimed at bringing the best and most diverse students into scientific jobs at the company. One from the UK educated university students in a week–long program on what it is like to work in the pharmaceutical industry. In the other, middle school girls across the US were encouraged become scientists through a series of hands–on human genetics activities.
Employees were recognized for their successful work in attracting more diverse patients to clinical trials for new medicines in the GSK drug pipeline, and for providing new tools for healthcare professionals to help provide culturally relevant coaching on how to improve health. Commented Tachi Yamada, Chairman, R&D, in presenting the awards, "A spotlight on diversity helps us discover medicines for all the patients in need."
Highlighted at the awards event were not–for–profit, exemplary healthcare initiatives financially supported by GSK because of their success in bettering the lives of underserved children
"Diversity is a win for GSK and a win for our customers, patients, and communities," said Ziegler. "It's all about good business."
About GlaxoSmithKline
GlaxoSmithKline is one of the world's leading research–based pharmaceutical and health care companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For more information on GlaxoSmithKline, visit www.gsk.com
Read about GSK's commitment to diversity at http://www.gsk.com/about/diversity.htm
The information below is the complete list of Multicultural Marketing and Diversity projects recognized by GlaxoSmithKline today.
Employee Attraction, Development, or Retention:
- Winning entry: Residential Chemistry Training Experience (UK)
- Honourable Mention: Consumer Healthcare Hispanic Employee Network (US)
Multicultural Marketing
- Winning entry: In–language Information about Hepatitis B and Epivir HBV (US)
Multicultural Sales
- Winning entry: Consumer Healthcare Multicultural Brands Initiative (US)
Community Outreach
- Winning entry: Sally Ride Science Festivals – GSK Street Fair Booth and Workshops (US)
- Winning entry: GSK IMPACT Awards (Philadelphia, UK)
- Honourable Mention: Artwork from the HIV Community (US)
Operational Distinction
- Winning entry: Diverse Patient Representation in Clinical Studies (US)
Work in Progress
- Winning entry: Multicultural Marketing Pilot for NiQuitin CQ (UK)
- Winning entry: Essential Connections (US)
- Honourable Mention: Health Literacy Project (US)
| GSK Belgium most desirable place to work | Close |
|---|
GSK Belgium wins national award for the most desirable place to work
Released: 26 September 2005
GlaxoSmithKline has received a perfect score of 100 per cent from the US Human Rights Campaign Foundation's 2005 Corporate Equality Index, an annual report card on corporate America's treatment of gay, lesbian, bisexual and transgender (GLBT) employees, customers and investors.
The perfect rating was pursued by a network of RTP employees who participate in the company's diversity initiative and in the Gay and Lesbian Support Network (GLSN). The networks –– associations of employees who have common interests –– provide resources to the business as well as professional growth and personal support for the participants. They advise on employee recruitment, retention, and external marketing efforts. Current US networks include the African American Alliance, the Asian Employee Support Group, the Gay and Lesbian Support Network, and the Hispanic Network. Women's Leadership groups are also a key component of GSK's diversity strategy.
"This recognition indicates that GSK is committed to creating an inclusive environment for all employees, customers, and external stakeholders, and in particular, for those who are members of the GLBT community," said US Pharma HIV Marketing VP Peter Hare, who is GLSN executive sponsor.
Consumer Healthcare President Jack Ziegler, who is executive sponsor of GSK's diversity initiative, noted that the networks have contributed to GSK's ability to respond to multicultural customers' needs, and to collaborate more effectively with community leaders to provide better healthcare solutions for underserved groups. "Our diversity initiative, including our employee networks, is a win–win for GSK, our customers, patients, and communities."
| GSK best performing pharma in Hong Kong | Close |
|---|
GSK rated best performing pharma company in Hong Kong
Released: 27 Feb 2004
GlaxoSmithKline Hong Kong is the best performing pharmaceutical company in Hong Kong, according to a survey of health professionals.
The survey was conducted by Synovate Market Research Limited. A total of 80 health professionals, mainly doctors, were asked in face–to–face interviews to evaluate the performance of major players in the pharmaceutical industry in four areas – overall company image, sales representative services, logistic services and medical educational support.
The findings show that GSK is now ranked top in all four and the only company to have improved in each area assessed. That puts the company ahead of both Pfizer and AstraZeneca, which were ranked first and second in a similar survey conducted in 2001.
"We are delighted to learn the result of this survey," says C S Park, Managing Director, Pharmaceuticals, GSK Hong Kong. "It reflects the efforts and resources of our sales effectiveness plan that has been implemented since the formation of GSK. I trust we now have a better team to serve the medical professionals in Hong Kong and the community as a whole."
| Top honours for GSK's environmental reporting | Close |
|---|
GSK wins top honours for environmental reporting
Released: 26 Feb 2004
GlaxoSmithKline won an award for its environmental reporting at the ACCA UK Awards held in London on 24 February.
The Association of Chartered Certified Accountants (ACCA) presented GSK with the first–place award at their 2003 Awards for Sustainability Reporting. Jim Hagan, Vice President, Corporate Environment, Health and Safety (EHS), accepted the award on behalf of GSK.
GSK received the honour for its 2002 EHS Report, The Impact of Medicines: Sustainability in Environment, Health and Safety. The report was commended for its detailed coverage of the company's EHS framework and ten year Plan for Excellence, in addition to wide–ranging performance data and independent verification.
"We have a structured and strong EHS programme at GSK and this is reflected in our EHS report," said Jim. "GSK and its heritage companies have reported our EHS programmes and progress since 1993. We look to be leaders in the industry and this award demonstrates our success. I especially want to thank Nancy English and her team, who put the report together every year. I also want to recognise all the people throughout the company in GMS, R&D and Commercial, who provided data and information that formed the basis for the winning report."
The ACCA recognises transparency in environmental, social and sustainability reporting and rewards organisations that report and disclose information in the most complete and credible way. They look for organisations to address their key impacts and provide demonstrable examples of progress.
| GSK voted best company in UK SMaRT awards | Close |
|---|
GSK voted best company in UK SMaRT awards
Released: 11 Feb 2004
GlaxoSmithKline Consumer Healthcare was voted the UK's Best Overall Company at the recent SMaRT Awards (Sales, Marketing and Retail Training), run by the Pharmacy magazine and UK pharmacy chain Numark.
The SMaRT Awards won were:
Best Overall Company – In spite of stiff competition from Pfizer, Novartis, and J&J MSD, the readers of Pharmacy Magazine, Training Matters and Pharmacy Products review voted GSK the Best Overall Company. Peter Hinkley, Sales Director for Consumer Healthcare UK (pictured left) accepted the award on behalf of GSK.
Best Educational Initaitive for Pharmacists – won by the Flixonase brand team for their ongoing educational initiatives used in trade press to support the POM (prescription only medicine) to over–the–counter switch.
Best Representation Award – awarded to Mike Walker, Field Sales Manager, Sales Pharmacy Channel, for the second year running in recognition of GSK's Consumer Healthcare UK sales force.
The company also received 'Highly Commended' mentions in the 'Best National Account Management' and 'Best Educational Initiative for Pharmacy Assistants' categories. The latter in recognition of the Commercial Education team for their PharmAssist module on Allergy and Hayfever.
| GSK second most respected healthcare | Close |
|---|
GSK ranked second most respected healthcare company by FT/PwC survey
Released: 23 Jan 2004
In a special report published this week by the UK Financial Times in conjunction with Price Waterhouse Coopers on the world's most respected companies, GlaxoSmithKline was ranked second in the healthcare sector, after Pfizer.
This was the view expressed by more than 900 chief executives in 20 countries, and boosted GSK's position in the rankings from third place in 2002. Johnson and Johnson, who were voted in first place in 2002, dropped to equal fourth alongside Merck in the latest survey, with Novartis number three. The top five companies respected overall regardless of sector, were GE, Microsoft, Toyota, IBM and Wal–Mart respectively.
In addition to interviewing senior executives, additional questions were asked of other stakeholder groups, including fund managers on the best creators of shareholder value, and journalists and campaigning organisations on corporate responsibility, integrity and corporate governance. GSK was ranked 35 in respect of corporate responsibility, and 28 in relation to the company's ability to create shareholder value.
| Bob Ingram awarded King Legacy Award | Close |
|---|
Bob Ingram awarded King Legacy Award
Released: 19 Jan 2004
Bob Ingram has been awarded the Martin Luther King Jr. Legacy Award, recognising his efforts in national and international service on behalf of GSK.
Bob received the honour on Sunday, 18 January at the Annual International Salute to Dr. Martin Luther King, Jr., in Washington, DC. The award, presented as a tribute to Dr. King's legacy, is given each year to recognise the contributions of individuals and groups who have positively impacted the national and international communities.
Past award recipients include UN Secretary–General Kofi Annan, US Secretary of State Colin Powell, US Surgeon–General David Satcher, former US Senator Bob Dole, and a host of US ambassadors to South Africa, Great Britain and Germany.
| GSK wins Community Relations Award | Close |
|---|
GSK's Science in the Summer wins Community Relations award in US
Released: 12 Dec 2004
The GSK Science in the Summer programme, funded by GSK's Global Community Partnerships Program in Philadelphia and administered by the American Association for the Advancement of Science, has received first place honours in a community relations awards programme.
On 3 December, Science in the Summer was recognised by the Public Relations Society of America – Philadelphia Chapter for excellence and creativity in community relations.
The free science education programme features hands–on activities and experiments designed to teach children basic scientific concepts, demonstrate how science is directly related to their every–day life, and get them excited about studying science.
Now in its 17th year, more than 60,000 children have participated in the program, which was created by Dr. Virginia Cunningham, Director and Team Leader of Environment, Health and Safety Product Stewardship at GSK.
Just this past summer alone, more than 6,000 local elementary school children participated in the programme at Philadelphia–area libraries. The experiment–oriented courses take advantage of children's natural curiosity and the fact that they learn best by doing. Courses include bioscience, chemistry, paleontology, physical science/electricity, and simple machines (how machines work) that are taught by certified teachers. Each course is made up of four 45–minute classes given over the course of a week to groups of 15 students in two age groups: those entering second and third grades and those entering fourth through sixth grades.
"We have been able to really spread the word about Science in the Summer throughout Philadelphia," said Emily Gerasimoff, Global Community Partnerships. "We're pleased to be recognized with an award for our efforts, and even more pleased that so many children and parents are now aware of this outstanding programme."
| GSK recognised for leadership | Close |
|---|
GSK recognised for leadership in alleviating tropical diseases; JP Garnier receives award
Released: 04 Dec 2004
GlaxoSmithKline to Be Cited for Commitment to Tropical Diseases ; CEO to Speak at American Society of Tropical Medicines Annual Meeting
Philadelphia, December 4, 2003 – GlaxoSmithKline (GSK) CEO J. P. Garnier will be honored this evening by The American Society of Tropical Medicine and Hygiene (ASTMH) at the Society's annual meeting being held in Philadelphia. Dr. Garnier will accept the award in recognition of GSK's leadership in alleviating tropical infectious disease worldwide for the improvement of global health. The award will be presented by Dr. William Petri, Jr., President of ASTMH
GSK will be cited for its vital contribution to healthcare in developing countries through action in three areas: investing in research & development that target infectious disease particularly affecting the developing world; preferential pricing of antiretrovirals, antimalarials and vaccines; and for community investment activities and partnerships that foster effective health care.
In addition to accepting the Society's award, Dr. Garnier will deliver the keynote address to the group, speaking on GSK's success in creating public–private partnerships as a model for combating tropical disease. In his remarks, Garnier is expected to say that while the world is responding to the immense challenges of developing world diseases such as HIV/AIDS, TB and malaria, "...lasting change can only be secured through partnership and collaboration."
Dr. Garnier will also discuss the work that GSK is doing along with the World Health Organization in the Global Programme to Eliminate Lymphatic Filariasis (LF). Also known as elephantiasis, LF is one of the world's leading causes of disability and disfigurement. GSK is committed to donating as much albendazole medicines as is required to eliminate the disease from the world by 2020. To date, the company has donated 240 million treatments to 38 countries. After just a few years of program activity, an estimated 90–100 million people have been reached, and several countries (including Egypt and several Pacific Islands) are seeing sharp declines in infection levels.
| GSK named in 100 Best Companies | Close |
|---|
GSK named to 100 best companies in U.S. by Working Mother Magazine
Released: 23 Sept 2004
GSK named to 100 Best Companies in U.S. by Working Mother Magazine
Working Mother magazine has named GSK one of the 100 Best Companies in the U.S. This is GSK's third year to receive the award, which continues the tradition of our legacy companies and speaks to GSK's continued commitment to working families. GSK offers a "solid slate of perks for working parents" according to the magazine's overview. In the family arena, GSK scored highly for its access to childcare, scholarships for teens, and elder assessment program. GSK was also noted for employees' increased use of flexible work arrangements and an increase of women in management. Working Mother magazine reaches more than 3 million readers and is the only US magazine for career–committed mothers. Its 18–year signature "100 Best Companies for Working Mothers" serves as a benchmark for work/life practices in corporate America. The magazine will honor the winning companies at a gala awards ceremony at the Work/Life Congress in New York September 29–October 1. The complete list of the 100 Best Companies appears in the Ocotober issue of Working Mother and at www.workingmother.com.
| GSK is largest charity donor | Close |
|---|
GSK gives largest amount in The Guardian Giving List
Released: 17 Nov 2003
GSK gives largest amount in The Guardian Giving List 2003
GlaxoSmithKline (GSK) has, for the second consecutive year, been recorded as giving the largest amount to global good causes of any FTSE 100 company, according to the Guardian's Giving List published today.
The Giving List reports GSK's community investment in 2002 as £132.99m, equivalent to 2.41% of pre–tax profit. This includes cash investment of £101.76m in community partnership activities, plus £25.96m of 'in–kind' product donations including disaster relief and other humanitarian relief programmes. Also included is a global £5.28m cost for operational management of the programmes. The Giving List figures do not include £112m for GSK's Patient Assistance Programme in the US, which provides discounts on GSK medicines for patients on lower incomes. When the Patient Assistance Programme is added back in, GSK's community investment (excluding management costs) rises to £239.7m, equivalent to 4.3% of pre–tax profit.
The Giving List is published annually by the Guardian Newspaper and ranks participating UK companies according what they contribute to communities. It is based on a benchmarking exercise carried out by Business in the Community's (BitC) PerCent Club, a forum that encourages companies to donate at least one per cent of pre–tax profits to good causes and community involvement.
Justine Frain, VP Global Community Partnerships, said: "While our key measure is the success of our community programmes in changing behaviour and improving human life, we are proud that the Guardian's Giving List for a second year identifies GSK as the largest corporate donor in the UK. GSK is making a diverse and extensive contribution to meet the needs of society across the globe. The leadership goal we have set for GSK extends beyond our science, products and marketing expertise, to encompass the more holistic role we play in society."
GSK's community investment targets health and education. Working alongside partners, our public health programmes are reaching millions of people with HIV/AIDS, malaria and lymphatic filariasis. and last year our humanitarian product donations were sent to over 70 countries. National and local partnerships across the world are supporting under–served communities. The company also supports GSK employees through funding and employee volunteering initiatives.
Highlights from 2002 include:
Investment of £239.7million in global community activities, product donations and charitable contributions – more than any other UK company. This is equivalent to 4.3 per cent of pre–tax profit and includes £127.7 million invested in community programmes and initiatives plus £112 million on US patient assistance programmes.
GSK's leading role in the global effort to fight lymphatic filariasis (elephantiasis). This disabling and disfiguring disease affects 120 million people and threatens a further one billion in some of the poorest nations in the world. As part of our 20–year, $1 billion, commitment to eliminate the disease, GSK donated 66 million tablets of our preventative treatment albendazole to 31 countries in 2002. On 25 July 2003, 10 million people in Sri Lanka, more that half of the country's population, was given a free GSK medicine in a single day.
Increased shipments of Combivir HIV/AIDS treatment at preferential prices to the developing world to over 6 million tablets, up from 2.2 million in 2001. Extension of voluntary licence for manufacture and sale of antiretrovirals. GSK believes that it has a responsibility to make its products as affordable as possible in the poorest countries. We now offer a single, sustainable, not–for–profit preferential price for each of our anti–retrovirals (ARVs) and anti–malarials to a wide range of customers in the Least Developed Countries and sub–Saharan Africa – a total of 63 countries. To date, GSK has secured over 150 arrangements to supply preferentially priced HIV/AIDS medicines to 56 countries. In the six months from April to September 2003, GSK shipped over 6 million tablets of preferentially priced Combivir. On 16 October 2003, GSK reduced the price of Combivir down to 65 cents per day and extended the voluntary licence granted to Aspen Pharmacare, Sub–Saharan Africa's largest generics company, for the manufacture and sale of antiretrovirals, to include both the public and private sectors and all countries in Sub–Saharan Africa.
Continuing progress in our community investment programmes in the developing world. In 2002, GSK's Positive Action programme which provides HIV education, care and community support, backed 25 international programmes in 32 countries, including Tanzania, Ethiopia and Zambia. In addition, we provided £320,000 to support the PHASE initiative (Personal Hygiene And Sanitation Education) in Kenya, Uganda, Nicaragua and Peru. PHASE targets school children and aims to reduce diarrhoea–related disease. The scheme's success was recognised when it was awarded the 2002 International Business Leaders Forum Award for International Corporate Citizenship.
Confirmation of GSK's belief that it has the industry's most extensive portfolio of Diseases of the Developing World (DDW) R&D projects and that we are the only company undertaking research into the prevention and treatment of all three of the World Health Organization's priority diseases – HIV/AIDS, tuberculosis and malaria. Our research into DDW is based at state–of–the–art, dedicated facilities in Tres Cantos, Spain. This is in addition to our HIV/AIDS and vaccines R&D programmes.
£12.6 million spent in the UK on charitable contributions and community investment. The programmes supported included a £1 million commitment over four years to fund INSPIRE (INnovative Scheme for Post–docs In Research and Education) which boosts science education in UK schools and the International Impact Awards which recognise excellence in the work of voluntary community healthcare organisations across the UK.
Increased support for programmes to improve access to medicines for low–income senior citizens and the disabled in the US who lack prescription drug coverage. In late 2001, GSK launched the Orange Card, which offers savings on the company's prescription medicines and was the first programme of its kind in the US. In addition, in 2002, GSK's Patient Assistance Program provided medicines worth over £112 million to more than 400,000 low income patients in the US who do not have medical insurance.
GSK publishes a Corporate and Social Responsibility Report, which covers the most pressing issues that are core to GSK's business and have generated significant interest from external stakeholders. It contains sections on medicines for the developing world; community investment; research & development, including diseases of the developing world and ethical issues in R&D; developing our employees; supporting human rights; caring for the environment; business ethics and the management of corporate social responsibility at GSK. Many of the sections also feature case studies on each subject, demonstrating GSK's approach and determination to demonstrate leadership in all aspects of its business.
The review can be downloaded from the company's website at www.gsk.com or is available on request from GSK.
| GSK wins Supportive Employer Award | Close |
|---|
GSK Poland wins Supportive Employer award
Released: 29 Oct 2003
GSK Poland wins Supportive Employer award
Earlier this month it was announced that GlaxoSmithKline Pharmaceuticals Poland was the winner of the prestigious "Supportive Employer" award for its employment restructuring programme and outplacement support for employees.
GSK was up against 12 other finalists competing for the award, which was organised by the leading Polish daily newspaper Rzeczpospolita and IMC Kariera. Other contenders for the award included Pepsi–Cola General Bottlers, Nordea Insurance, Lafarge, Centra–Exide and Polpharma SA, one of GSK Poland's main competitors, however the judges decision was unanimous.
GSK was recognised for the restructuring of the Poznan Site in 2001 and 2002, which affected 300 employees. The jury appreciated the broad scope of support, involving occupational counselling, assistance in searching for a new job, internal communication, employee evaluation mechanisms and the caring approach to the people leaving the Company. The award also highlighted GSK's HR management standards delivered by the HR Shared Services.
"We believe that this award will enhance the position of GSK," Mark Loughran, Vice President and General Manager, GSK Pharmaceuticals Poland. "Not only as the leading employer in Poland," but also as a multinational corporation with successful local operations."
